Abstract:Theranostics cover emerging technologies for cell biomarking for disease diagnosis and targeted introduction of drug ingredients to specific malignant sites. Theranostics development has become a significant biomedical research endeavor for effective diagnosis and treatment of diseases, especially cancer. An efficient biomarking and targeted delivery strategy for theranostic applications requires effective molecular coupling of binding ligands with high affinities to specific receptors on the cancer cell surface. Bioaffinity offer a unique mechanism to bind specific target and receptor molecules from a range of non‐targets. The binding efficacy depends on the specificity of the affinity ligand towards the target molecule even at low concentrations. Aptamers are fragments of genetic materials, peptides or oligonucleotides which possess enhanced specificity in targeting desired cell surface receptor molecules. They can function to navigate drug molecules to desired sites with reduced systemic cytotoxicity to healthy cells. The binding specificity of aptamers is driven by distinctive structural transformations, resulting from ionic and molecular charge distribution induced by the target receptor and surrounding microenvironment. Aptamer‐target binding results from several inter‐molecular interactions including hydrogen bond formation, aromatic stacking of flat moieties, hydrophobic interaction, electrostatic and van der Waals interactions. Advancements in SELEX assay has created the opportunity to artificially generate aptamers that specifically bind to desired cancer and tumor surface receptors with high affinities. This article discusses the potential application of molecular dynamics (MD) simulation to advance aptamer‐mediated receptor targeting in targeted cancer therapy. MD simulation offers real‐time analysis of the molecular drivers of the aptamer‐receptor binding and generate optimal receptor binding conditions for theranostic applications. The article also provides an overview of different cancer types with focus on receptor biomarking and targeted treatment approaches, conventional molecular probes and aptamers that have been explored for cancer cells targeting.This article is protected by copyright. All rights reserved

Emerging Biohybrids of Aptamer-Based Nano-Biosensing Technologies for Effective Early Cancer Detection

Novel Insights into the Role of Aptamers in the Fight Against Cancer.

Leveraging Nanomaterials for Ultrasensitive Biosensors in Early Cancer Detection: A Review

Aptamers: Versatile Molecular Recognition Probes for Cancer Detection.

Aptamer-Conjugated Nanomaterials for Specific Cancer Diagnosis and Targeted Therapy

Aptamer-Based Targeting of Cancer: A Powerful Tool for Diagnostic and Therapeutic Aims

Using Aptamer–Nanoparticle Conjugates for Cancer Cells Detection

Advances in the detection of breast cancer by nucleic acid aptasensor

Bioapplications of Cell-SELEX-Generated Aptamers in Cancer Diagnostics, Therapeutics, Theranostics and Biomarker Discovery: A Comprehensive Review

Recent progress in Nanomaterial based biosensors for the detection of cancer biomarkers in human fluids

Optical Biosensors for Detection of Cancer Biomarkers: Current and Future Perspectives

Aptamer-based approaches for in vitro molecular detection of cancer

Emerging Multifunctional Carbon‐Nanomaterial‐Based Biosensors for Cancer Diagnosis

Aptamer-based fluorescent sensors for the detection of cancer biomarkers.

Aptamers: Active Targeting Ligands for Cancer Diagnosis and Therapy

Aptamer‐Based Cancer Cell Analysis and Treatment

Cell-SELEX-based Aptamer-Conjugated Nanomaterials for Cancer Diagnosis and Therapy

Biomedical Application Of Nanotechnology In Cancer Early Diagnosis

Recent Advance Of Biocompatible Nanomaterials For The Identification, Diagnosis, And Treatment Of Cancers

Advancing Aptamers as Molecular Probes for Cancer Theranostic Applications—The Role of Molecular Dynamics Simulation